(BFRG) Bullfrog AI Holdings - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •

BFRG: AI/ML Platform, siRNA Therapeutics, Oncology Treatments

Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company leveraging artificial intelligence (AI) and machine learning (ML) to analyze medical and healthcare datasets. The companys flagship platform, bfLEAP, is designed to optimize preclinical and clinical data analysis, accelerating drug discovery and development. Bullfrog AI has established strategic licensing agreements with academic institutions, including George Washington University for siRNA targeting Beta2-spectrin to treat hepatocellular carcinoma, obesity, and liver diseases, and Johns Hopkins University for a Mebendazole formulation targeting glioblastoma and other cancers. Founded in 2017 and headquartered in Gaithersburg, Maryland, the company operates at the intersection of AI-driven analytics and precision medicine.

From a technical standpoint, BFRG has shown recent price weakness, trading below its 20-day, 50-day, and 200-day moving averages. The stocks average true range (ATR) of 0.41 indicates moderate volatility. The 20-day average volume of 1.93 million shares reflects relatively thin liquidity, which can amplify price movements. The current price of $1.80 is below the 20-day SMA of $2.73, suggesting near-term bearish momentum.

Fundamentally, Bullfrog AIs market cap of $22.83 million reflects its early-stage positioning in the AI-driven biopharma space. The price-to-book (P/B) ratio of 5.66 indicates a premium valuation relative to book value, likely driven by expectations for future growth. The price-to-sales (P/S) ratio of 530.83 is elevated, signaling investor confidence in the companys long-term revenue potential despite current losses.

3-Month Forecast: Based on and , BFRG is expected to face headwinds in the near term, with technical indicators pointing to continued weakness. The stock may test support levels below $1.80, with potential resistance near the 20-day SMA of $2.73. However, the companys strategic partnerships and focus on AI in biopharma could attract investor interest, potentially stabilizing or recovering prices within the forecast period. The high P/S ratio suggests expectations for future growth, but near-term price action may remain volatile due to thin liquidity and bearish momentum.

Additional Sources for BFRG Stock

BFRG Stock Overview

Market Cap in USD 23m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Equipment
IPO / Inception 2023-02-13

BFRG Stock Ratings

Growth 5y -54.0%
Fundamental -
Dividend 0.0%
Rel. Strength Industry -55.5
Analysts -
Fair Price Momentum 1.09 USD
Fair Price DCF -

BFRG Dividends

No Dividends Paid

BFRG Growth Ratios

Growth Correlation 3m -1.9%
Growth Correlation 12m -53.8%
Growth Correlation 5y -72.9%
CAGR 5y -48.41%
CAGR/Max DD 5y -0.58
Sharpe Ratio 12m -1.45
Alpha -69.11
Beta 2.31
Volatility 100.56%
Current Volume 259.8k
Average Volume 20d 542.5k
What is the price of BFRG stocks?
As of March 14, 2025, the stock is trading at USD 1.59 with a total of 259,806 shares traded.
Over the past week, the price has changed by -15.87%, over one month by -59.85%, over three months by -28.38% and over the past year by -55.59%.
Is Bullfrog AI Holdings a good stock to buy?
No, based on ValueRay Analyses, Bullfrog AI Holdings (NASDAQ:BFRG) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -54.04 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BFRG as of March 2025 is 1.09. This means that BFRG is currently overvalued and has a potential downside of -31.45%.
Is BFRG a buy, sell or hold?
Bullfrog AI Holdings has no consensus analysts rating.
What are the forecast for BFRG stock price target?
According to ValueRays Forecast Model, BFRG Bullfrog AI Holdings will be worth about 1.3 in March 2026. The stock is currently trading at 1.59. This means that the stock has a potential downside of -17.61%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 1.3 -17.6%